What is the appropriate management for a hyperplastic gastric polyp containing focal intestinal metaplasia in an adult patient (≥50 years)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Management of Hyperplastic Gastric Polyp with Focal Intestinal Metaplasia

For a hyperplastic gastric polyp containing focal intestinal metaplasia in an adult ≥50 years, you should test and eradicate H. pylori, resect the polyp if >1 cm (or if symptomatic/pedunculated regardless of size), carefully evaluate the surrounding gastric mucosa for synchronous neoplasia and extent of intestinal metaplasia, and implement endoscopic surveillance based on the stage of chronic atrophic gastritis. 1

Immediate Management Steps

1. H. pylori Testing and Eradication

  • Test all patients with hyperplastic polyps for H. pylori and treat if positive 1, 2
  • This is critical because up to 70% of hyperplastic polyps regress after H. pylori eradication 1
  • Perform repeat endoscopy 3-6 months after eradication to assess for polyp regression before considering resection 1

2. Polyp Resection Criteria

Resect the polyp if it meets any of these criteria: 1

  • Size >1 cm (increased dysplasia risk of 1.9-19%)
  • Pedunculated morphology
  • Symptomatic (bleeding, obstruction)
  • Size >3 cm (always resect regardless of H. pylori status due to high dysplasia/cancer risk)

Important caveat: Even if the polyp is <1 cm, the presence of focal intestinal metaplasia within the polyp itself warrants careful consideration for resection to exclude dysplasia, as hyperplastic polyps with dysplasia carry a 6% risk of synchronous neoplastic lesions in surrounding mucosa 1.

3. Systematic Gastric Mucosal Evaluation

This is critical and often overlooked. The surrounding gastric mucosa requires thorough assessment because: 1, 2

  • Hyperplastic polyps are associated with chronic gastritis, gastric atrophy (GA), and gastric intestinal metaplasia (GIM) in the background mucosa
  • Up to 6% risk of synchronous neoplastic lesions exists when dysplasia is present in the polyp 1
  • The presence and extent of GIM in the surrounding mucosa determines surveillance intervals

Obtain targeted biopsies of: 2

  • Any visible mucosal abnormalities suggesting GIM or atrophic gastritis
  • Follow existing protocols for GIM detection (consider OLGA/OLGIM staging if available)

Surveillance Strategy

If No Dysplasia in the Polyp:

Base surveillance on the extent of GIM and atrophic gastritis in the surrounding mucosa: 3, 1

  • Extensive or incomplete GIM: These patients are at higher risk and surveillance may be reasonable through shared decision-making 3
  • Limited GIM: The 2020 AGA guidelines suggest against routine surveillance, though this remains conditional with very low quality evidence 3
  • Follow the stage of chronic atrophic gastritis (CAG) to determine surveillance intervals 1

If Dysplasia is Present in the Polyp:

After complete resection: 2

  • Low-grade dysplasia: Follow-up endoscopy at 1 year
  • High-grade dysplasia: Follow-up endoscopy at 6 months

If resection is incomplete or only biopsied: 2

  • High-grade dysplasia: Follow-up at 3 months
  • Low-grade dysplasia: Follow-up at 6 months

Key Risk Factors for Neoplastic Transformation

Be aware that certain features significantly increase malignancy risk in hyperplastic polyps: 4, 5

  • Age ≥65 years (OR 2.60)
  • Size ≥20 mm (OR 4.63, increasing with larger size thresholds)
  • Intestinal metaplasia within the polyp (OR 3.65) - your patient has this
  • Size >25 mm carries 10-fold increased risk of neoplastic transformation
  • Size ≥50 mm shows risk of high-grade dysplasia

Common Pitfalls to Avoid

  1. Don't skip H. pylori testing - Many polyps will regress with eradication alone, avoiding unnecessary resection
  2. Don't ignore the surrounding mucosa - The field defect (GIM, atrophic gastritis) often poses greater long-term cancer risk than the polyp itself
  3. Don't assume small polyps are benign - The presence of intestinal metaplasia within the polyp warrants heightened vigilance regardless of size
  4. Don't perform surveillance based solely on the polyp - Surveillance intervals should be determined by the stage of CAG and extent of GIM in the background mucosa 1

PPI Considerations

If the patient is on long-term PPIs, re-evaluate the appropriateness, dose, and alternative treatments 1. However, valid PPI indications do not require discontinuation in the presence of gastric polyps 2.

References

2
Research

AGA Clinical Practice Update on Management of Gastric Polyps: Expert Review.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2026

Related Questions

How should I explain to a patient with a hyperplastic gastric polyp containing intestinal metaplasia the need for H. pylori testing, eradication therapy (PPI plus amoxicillin and clarithromycin or metronidazole if penicillin‑allergic), repeat endoscopy in 3–6 months, possible polyp removal if >1 cm or symptomatic, and the follow‑up surveillance schedule?
How should hyperplastic gastric polyps be managed, including indications for removal, biopsy, H. pylori testing, and follow‑up?
How should I manage an antral polyp in the setting of Helicobacter pylori infection?
What is the recommended endoscopic biopsy protocol, Helicobacter pylori testing and eradication regimen, and surveillance schedule for gastric intestinal metaplasia?
For a 5 mm hyperplastic polyp in the transverse colon, how often should colonoscopy be performed?
What are the first‑line antipsychotics, including generic and brand names, pharmacologic basis, and recommended dosing regimens, for treating chronic psychosis with prominent visual and auditory hallucinations?
What medications can be used to treat restless‑leg syndrome in adults?
Does the increased T2 signal in the cerebellar white matter on MRI correlate with my positive antinuclear antibody (ANA) screening and anti‑RNP (ribonucleoprotein) antibody level of 4.7 U (normal 0‑0.9 U)?
What dose of vaginal micronized progesterone is recommended for uterine‑lining thickening during the luteal phase in a reproductive‑age woman?
How should I explain to a patient with a hyperplastic gastric polyp containing intestinal metaplasia the need for H. pylori testing, eradication therapy (PPI plus amoxicillin and clarithromycin or metronidazole if penicillin‑allergic), repeat endoscopy in 3–6 months, possible polyp removal if >1 cm or symptomatic, and the follow‑up surveillance schedule?
What is the appropriate tapering regimen for bupropion (Wellbutrin) 150 mg daily in a patient experiencing hallucinations?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.